LianBio
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which … Read more
LianBio (LIANY) - Net Assets
Latest net assets as of December 2023: $581.20 Million USD
Based on the latest financial reports, LianBio (LIANY) has net assets worth $581.20 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($617.96 Million) and total liabilities ($36.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $581.20 Million |
| % of Total Assets | 94.05% |
| Annual Growth Rate | 9.36% |
| 5-Year Change | -75.03% |
| 10-Year Change | N/A |
| Growth Volatility | 216.49 |
LianBio - Net Assets Trend (2019–2024)
This chart illustrates how LianBio's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LianBio (2019–2024)
The table below shows the annual net assets of LianBio from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $62.87 Million | -89.18% |
| 2023-09-30 | $581.20 Million | +97.92% |
| 2022-09-30 | $293.65 Million | -24.19% |
| 2021-09-30 | $387.33 Million | +53.87% |
| 2020-09-30 | $251.72 Million | +526.42% |
| 2019-09-30 | $40.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LianBio's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13231066900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $27.58 Million | 43.87% |
| Other Components | $191.92 Million | 305.29% |
| Total Equity | $62.87 Million | 100.00% |
LianBio Competitors by Market Cap
The table below lists competitors of LianBio ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
$12.55 Million |
|
Radhika Jeweltech Limited
NSE:RADHIKAJWE
|
$12.55 Million |
|
Wellysun Inc
TW:6988
|
$12.56 Million |
|
Rocky Mountain Chocolate Factory
NASDAQ:RMCF
|
$12.56 Million |
|
Icape Holding
PA:ALICA
|
$12.55 Million |
|
Eden Research plc
PINK:EDNSF
|
$12.54 Million |
|
Goa Carbon Limited
NSE:GOACARBON
|
$12.54 Million |
|
OCR Group Bhd
KLSE:7071
|
$12.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LianBio's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 581,197,116 to 62,865,827, a change of -518,331,289 (-89.2%).
- Net income of 2,476,241 contributed positively to equity growth.
- Dividend payments of 550,697,079 reduced retained earnings.
- Other comprehensive income increased equity by 29,614,924.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.48 Million | +3.94% |
| Dividends Paid | $550.70 Million | -875.99% |
| Other Comprehensive Income | $29.61 Million | +47.11% |
| Other Changes | $274.62K | +0.44% |
| Total Change | $- | -89.18% |
Book Value vs Market Value Analysis
This analysis compares LianBio's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.55x to 0.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | $0.36 | $0.20 | x |
| 2020-09-30 | $2.06 | $0.20 | x |
| 2021-09-30 | $3.30 | $0.20 | x |
| 2022-09-30 | $2.41 | $0.20 | x |
| 2023-09-30 | $5.36 | $0.20 | x |
| 2024-09-30 | $0.58 | $0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LianBio utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.01x
- Recent ROE (3.94%) is above the historical average (-27.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -62.20% | 0.00% | 0.00x | 1.12x | $-28.29 Million |
| 2020 | -64.46% | 0.00% | 0.00x | 1.29x | $-161.54 Million |
| 2021 | -55.60% | 0.00% | 0.00x | 1.21x | $-231.92 Million |
| 2022 | -42.39% | 0.00% | 0.00x | 1.23x | $-136.15 Million |
| 2023 | 53.53% | 0.00% | 0.00x | 1.06x | $253.02 Million |
| 2024 | 3.94% | 0.00% | 0.00x | 1.01x | $-3.81 Million |
Industry Comparison
This section compares LianBio's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LianBio (LIANY) | $581.20 Million | -62.20% | 0.06x | $12.55 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |